Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches.
暂无分享,去创建一个
[1] J. Mesirov,et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer , 2011, Proceedings of the National Academy of Sciences.
[2] Douglas A Lauffenburger,et al. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. , 2013, Cancer discovery.
[3] Alan Mackay,et al. Functional viability profiles of breast cancer. , 2011, Cancer discovery.
[4] Ji Luo,et al. A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis , 2012, Science.
[5] Donald P. McDonnell,et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance , 2014, Science Signaling.
[6] Zemin Zhang,et al. Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations , 2015, Proceedings of the National Academy of Sciences.
[7] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[8] R. Bernards,et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. , 2014, Cancer discovery.
[9] W. Hahn,et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. , 2013, The Journal of clinical investigation.
[10] R. Soldi,et al. A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer , 2013, Investigational New Drugs.
[11] William C. Hahn,et al. Towards systematic functional characterization of cancer genomes , 2011, Nature Reviews Genetics.
[12] Mark J. Ratain,et al. Tumour heterogeneity in the clinic , 2013, Nature.
[13] Bo Zhang,et al. A formal model for analyzing drug combination effects and its application in TNF-α-induced NFκB pathway , 2010, BMC Systems Biology.
[14] Ho-June Lee,et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. , 2014, Cancer cell.
[15] Philippe Dessen,et al. Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer , 2012, Clinical Cancer Research.
[16] Yun Zheng,et al. Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer , 2014, Epigenetics.
[17] Aik Choon Tan,et al. Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.
[18] R. Bernards,et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.
[19] M. Gore,et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer , 2014, British Journal of Cancer.
[20] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[21] T. Golub,et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.
[22] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[23] Marc Hafner,et al. Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines , 2013, Science Signaling.
[24] Laura Tolosi,et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. , 2009, The Journal of clinical investigation.
[25] E. Lander,et al. Lessons from the Cancer Genome , 2013, Cell.
[26] M. Spector,et al. Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.
[27] Dennis C. Friedrich,et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.
[28] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Marc Vidal,et al. COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.
[30] Thomas M Green,et al. A public genome-scale lentiviral expression library of human ORFs , 2011, Nature Methods.
[31] A. Ashworth,et al. Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. , 2011, Cancer research.
[32] W. Hahn,et al. PRKACA Mediates Resistance to HER2-Targeted Therapy in Breast Cancer Cells and Restores Anti-Apoptotic Signaling , 2014, Oncogene.
[33] H. Woo,et al. Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set , 2010, Molecular Cancer Therapeutics.
[34] Travis J Cohoon,et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. , 2013, Cancer cell.
[35] Li Ding,et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. , 2013, Cell reports.
[36] Benjamin Haibe-Kains,et al. Inconsistency in large pharmacogenomic studies , 2013, Nature.
[37] P. Meltzer,et al. NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses , 2014, PloS one.
[38] P. Meltzer,et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. , 2013, Cancer research.
[39] A. Ashworth,et al. Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers , 2014, Oncogene.
[40] Chris Albanese,et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. , 2012, The American journal of pathology.
[41] J. Weinstein,et al. mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug Activities , 2010, Molecular Cancer Therapeutics.
[42] H. Clevers,et al. Single Lgr5 stem cells build cryptvillus structures in vitro without a mesenchymal niche , 2009, Nature.
[43] Chris Sander,et al. Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets , 2013, Science Signaling.
[44] R. Bernards,et al. MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling , 2012, Cell.
[45] Nikhil Wagle,et al. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. , 2015, Cancer discovery.
[46] Robert Brown,et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling , 2012, Oncogene.
[47] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[48] M. Schuler,et al. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors , 2014, British Journal of Cancer.
[49] T. Phang,et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. , 2010, Cancer cell.
[50] C. Scott,et al. Prioritizing therapeutic targets using patient-derived xenograft models. , 2015, Biochimica et biophysica acta.
[51] Sridhar Ramaswamy,et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.
[52] Julian Downward,et al. The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer , 2012, Cell.
[53] A. McKenna,et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.
[54] J. Engelman,et al. Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer , 2013, Science Signaling.
[55] A. Sood,et al. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies , 2013, Investigational New Drugs.
[56] A. Ashworth,et al. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen , 2011, Proceedings of the National Academy of Sciences.
[57] J. Weinstein,et al. High Resolution Copy Number Variation Data in the NCI-60 Cancer Cell Lines from Whole Genome Microarrays Accessible through CellMiner , 2014, PloS one.
[58] J. Keats,et al. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. , 2009, Blood.
[59] Yiling Lu,et al. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.
[60] A. Ashworth,et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. , 2013, Cancer discovery.
[61] S. Gabriel,et al. A functional landscape of resistance to ALK inhibition in lung cancer. , 2015, Cancer cell.
[62] A. Iafrate,et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling , 2007, Proceedings of the National Academy of Sciences.
[63] Joel Greshock,et al. Molecular target class is predictive of in vitro response profile. , 2010, Cancer research.
[64] Hans Clevers,et al. Organoid Cultures Derived from Patients with Advanced Prostate Cancer , 2014, Cell.
[65] Erik Sahai,et al. Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling , 2015, Cancer cell.
[66] Joshy George,et al. Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.
[67] Jae Cheol Lee,et al. Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.
[68] Rajiv Narayan,et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition , 2013, Nature.
[69] A. Ashworth,et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. , 2008, Cancer cell.
[70] Steven J. M. Jones,et al. Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.
[71] Francisco J. Sánchez-Rivera,et al. Applications of the CRISPR–Cas9 system in cancer biology , 2015, Nature Reviews Cancer.
[72] A. Letai,et al. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis , 2014, Science Signaling.
[73] Martin A Nowak,et al. Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers , 2014, Proceedings of the National Academy of Sciences.
[74] Manuel Hidalgo,et al. Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.
[75] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[76] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[77] J. Mesirov,et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. , 2014, Cancer discovery.
[78] Mari Mino-Kenudson,et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.
[79] Jane Fridlyand,et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.
[80] Jan Koster,et al. NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome , 2010, Cell.
[81] Charles Giardina,et al. Intestinal organoids as tissue surrogates for toxicological and pharmacological studies. , 2013, Biochemical pharmacology.
[82] E. Cuppen,et al. Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures , 2014, Cell.
[83] P. Jänne,et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. , 2006, The Journal of clinical investigation.
[84] K. Badani,et al. Single luminal epithelial progenitors can generate prostate organoids in culture , 2014, Nature Cell Biology.
[85] Hayley E. Francies,et al. Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.
[86] T. Golub,et al. Genetic modifiers of EGFR dependence in non-small cell lung cancer , 2014, Proceedings of the National Academy of Sciences.
[87] F. Bosch,et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer , 2012, Nature Medicine.
[88] Robert Clarke,et al. Enhancing reproducibility in cancer drug screening: how do we move forward? , 2014, Cancer research.
[89] Karen Cichowski,et al. Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.
[90] Michael Peyton,et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.
[91] Thomas D. Wu,et al. A comprehensive transcriptional portrait of human cancer cell lines , 2014, Nature Biotechnology.